Derivatives of estra 1,3,5(10)triene-17-one,3-amino compounds and their use

• US 5,677,292 A
• Filed: 02/27/1996
• Issued: 10/14/1997
• Est. Priority Date: 11/17/1994
• Status: Expired due to Fees

• Current Assignee: Duquesne University of The Holy Ghost
• Original Assignee: Duquesne University of The Holy Ghost
• Inventors: Li, Pui-Kai, Selcer, Kyle W.
• Primary Examiner(s): Reamer, James H.
• Application Number:
  US08/607,797
• Time in Patent Office: 595 Days
• Field of Search: 514/167, 514/177, 552/303
• US Class Current: 514/169
• CPC Class Codes: C07J 41/0005 the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton

Abstract

This invention discloses compounds useful as steroid sulfatase inhibitors. The compounds comprise the formula (1) ##STR1## wherein (a) R is selected from the group consisting of hydrogen, a lower alkyl group, an alkoxy group, halogen, NH₂, NO₂, C.tbd.N and N═C═S; and (b) the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiols, estradiolesters, pregnenolone, substituted estrones, substituted dehydroepiandrosterones, substituted estradiols, substituted estradiolesters and substituted pregnenolone. The compounds also comprise the formula (5) ##STR2## wherein (a) R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, CO(C₁ -C₆ -alkyl); and (b) the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiol, estradiolester, pregnenolone, substituted estrones, substituted dehydroepiandrosterone, substituted estradiols, substituted estradiolesters and substituted pregnenolone. The invention also discloses methods of treating a patient therapeutically and prophylactically for estrogen dependent diseases with the compounds of this invention.

Claims

1. A method of therapeutically treating a patient for estrogen dependent comprising diseases providing a compound having the formula (5) ##STR29## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl) COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl) and the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiols, estradiolesters, pregnenolone, substituted estrones, substituted dehydroepiandrosterones, substituted estradiols, substituted estradiolesters and substituted pregnenolone,

incorporating said compound in a suitable pharmaceutical carrier;

administering a therapeutically effective dosage of said compound incorporated in said carrier to a patient; and

employing said method in therapeutically treating a patient for estrogen related diseases selected from the group consisting of breast cancer, ovarian cancer, vaginal cancer, endometrial cancer and endometriosis.

2. The method of claim 1, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

3. The method of claim 2, including administering said compound incorporated in said carrier to a patient by injection.

4. The method of claim 2, including administering said compound incorporated in said carrier to a patient by the parenteral route.

5. The method of claim 2, including administering said compound incorporated in said carrier to a patient by the oral route.

6. The method of claim 1, including administering said compound in said carrier to a patient topically.

7. The therapeutical method of claim 1 including employing the compounds having the species formula (6) ##STR30## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl).

8. The method of claim 7, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

9. The method of claim 8, including administering said compound incorporated in said carrier to a patient by the parenteral route.

10. The method of claim 8, including administering said compound incorporated in said carrier to a patient by the oral route.

11. The therapeutical method of claim 1 including employing the compounds having the species formula (7) ##STR31## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl).

12. The method of claim 11, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

13. The method of claim 12, including administering said compound incorporated in said carrier to a patient by the parenteral route.

14. The method of claim 12, including administering said compound incorporated in said carrier to a patient by the oral route.

15. The therapeutical method of claim 1 including employing the compounds having the species formula (8) ##STR32## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl).

16. The method of claim 15, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

17. The method of claim 16, including administering said compound incorporated in said carrier to a patient by the parenteral route.

18. The method of claim 16, including administering said compound incorporated in said carrier to a patient by the oral route.

19. A method of prophylactically treating a patient to provide protection as an estrogen depleting agent, the method comprising providing a compound having the formula (5) ##STR33## wherein (a) R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl);

and (b) the ring system ABCD represents a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiols, estradiolesters, pregnenolone, substituted estrones, substituted dehydroepiandrosterones, substituted estradiols, substituted estradiolesters and substituted pregnenolone,

incorporating said compound in a suitable pharmaceutical carrier;

administering a prophylactically effective dosage of said estrogen depleting compound incorporated in said carrier to a patient; and

employing said method in prophylactically treating a patient to provide protection as an estrogen depleting agent against an estrogen dependent disease selected from the group consisting of breast cancer, ovarian cancer, vaginal cancer, endometrial cancer and endometriosis.

20. The method of claim 19 including employing said carrier selected from the group consisting of physiologic saline and 5% dextrose in water.

21. The method of claim 20, if including administering said compound incorporated in said carrier to a patient by the parenteral route.

22. The method of claim 20, including administering said compound incorporated in said carrier to a patient by the oral route.

23. The method of claim 20, including administering said compound incorporated in said carrier to a patient topically.

24. The prophylactic method of claim 19 including employing the compounds having the species formula (6) ##STR34## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl).

25. The method of claim 24, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

26. The method of claim 25, including administering said compound incorporated in said carrier to a patient by the parenteral route.

27. The method of claim 25, including administering said compound incorporated in said carrier to a patient by the oral route.

28. The method of claim 25, including administering said compound incorporated in said carrier to a patient topically.

29. The prophylactic method of claim 19 including employing the compounds having the species formula (7) ##STR35## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl).

30. The method of claim 29, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

31. The method of claim 30, including administering said compound incorporated in said carrier to a patient by the parenteral route.

32. The method of claim 30, including administering said compound incorporated in said carrier to a patient by the oral route.

33. The method of claim 30, including administering said compound incorporated in said carrier to a patient topically.

34. The prophylactic method of claim 19 including employing the compounds having the species formula (8) ##STR36## wherein R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, and CO(C₁ -C₆ -alkyl).

35. The method of claim 34, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

36. The method of claim 35, including administering said compound incorporated in said carrier to a patient by the parenteral route.

37. The method of claim 35, including administering said compound incorporated in said carrier to a patient by the oral route.

38. The method of claim 35, including administering said compound incorporated in said carrier to a patient topically.